Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5289722 | 0.85 | DAO (0.36) | DAOKDM4CKMT2AKDM4ELMNA | |
| SCHEMBL3939509 | 0.80 | RPS6KB2 (0.42) | DAOKDM4CKMT2ALMNAHTT | |
| SCHEMBL5279684 | 0.75 | NPC1 (0.49) | DAOKMT2ALMNAMAPK1HTT | |
| SCHEMBL2399697 | 0.74 | DAO (0.47) | DAOKDM4CFFAR1KDM4E | |
| SCHEMBL8855371 | 0.74 | DAO (0.42) | DAOKDM4CFFAR1KDM4ELMNA | |
| SCHEMBL8540112 | 0.73 | DAO (0.41) | DAOKDM4CFFAR1KMT2ALMNA | |
| SCHEMBL7354171 | 0.71 | IAPP (0.41) | DAOKDM4CFFAR1KMT2ALMNA | |
| SCHEMBL8003191 | 0.71 | KMT2A (0.41) | KMT2ALMNAHTTL3MBTL1 | |
| SCHEMBL5285647 | 0.71 | ALOX5 (0.40) | KDM4CFFAR1KMT2AKDM4ELMNA | |
| SCHEMBL5285884 | 0.70 | DAO (0.52) | DAOKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | DAO 1438/4885KDM4C 4288/4885FFAR1 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.